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hepatocarcinoma cells to chemotherapeutic
drugs through inhibition of HBx-mediated NF-κB
activation
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Background: Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) is characterized by high
chemotherapy resistance; however, the underlying mechanism has not been fully clarified. In addition, HBx protein
has been reported to play a key role in virus-mediated hepatocarcinogenesis. Therefore, the present study aims to
investigate the role of HBx in the drug-resistance of HBV-related HCC and examine whether such drug-resistance
can be reversed by IFN-α treatment.
Methods: We established HBx-expressing cells by liposome-mediated transfection of HBx into the Huh7 cell line.
MTT, Annexin V/PI, and cell cycle assay were used for determining the cellular growth inhibition, apoptosis, and
growth arrest, respectively, after treatment with chemical drug. We further used tumor-bearing mice model to
compare the tumor growth inhibition efficacy of ADM and 5-FU between the Huh7-HBx group and the control
group, as well as the ADM + IFN-α or ADM + IMD treated group and the ADM treated group. SQ-Real time-PCR was
performed to analyze the expression of MDR-associated genes and anti-apoptotic genes. Moreover,
immunofluorescence and Western blotting were used to determine the subcellular localization of p65 and the
phosphorylation of IκBα.
Results: The IC50 values of Huh7-HBx cells against ADM and Amn were 2.317 and 1.828-folds higher than those of
Huh7-3.1 cells, respectively. The apoptosis ratio and growth arrest was significantly lower in Huh7-HBx cells after
treatment with ADM. The in vivo experiment also confirmed that the Huh7-HBx group was much more resistant to
ADM or 5-FU than the control. Furthermore, the expression of MDR-associated genes, such as MDR1, MRP1, LRP1,
and ABCG2, were significantly up-regulated in Huh7-HBx cells, and the NF-κB pathway was activated after HBx gene
transfection in Huh7 cells. However, combined with IFN-α in ADM treatment, the HBx induced drug-resistance in
Huh7-HBx cells can be partly abolished in in vitro and in vivo models. Moreover, we found that the NF-κB canonical
pathway was affected by IFN-α treatment, and the expression of anti-apoptotic genes, such as Gadd45β, Survivin,
and c-IAP-1 was down-regulated by IFN-α treatment in a dose-dependent manner.
Conclusions: HBx protein can induce MDR of HBV-related HCC by activating the NF-κB pathway, which can be
partly abolished by IFN-α treatment.
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Hepatocellular carcinoma (HCC) is resistant to chemo-
therapeutic drugs [1], The response rates for a single
cytotoxic agent are approximately 15, to 20, [2]. More-
over, only a few drugs can elicit therapeutic effect in
more than 20, of patients with HCC [3]. The use of che-
motherapeutic agents for advanced HCC has been very
disappointing. Recently, further studies have demon-
strated that the unsatisfactory effect of chemotherapy on
HCC is associated with the over-expression of multi-
drug resistance gene (MDR1) and consequent high levels
of P-glycoprotein in HCC patients [4,5]. Furthermore,
HBV-integrated HCC has developed a significantly high
percentage of drug-resistance [6].
Hepatits B virus X (HBx) is a major HBV multi-
functional protein that may directly or indirectly contrib-
ute to the progression of chronic hepatitis B to HCC [7].
The over-expression of HBx protein can induce cell trans-
formation [8]. In addition, HBx protein can interact with
p53 tumor suppressor gene, and inactivate this “gene
guard” [9]. HBx protein has been confirmed to contribute
to NF-κB signaling pathway activation [10,11]. NF-κB has
a central role in the regulation of diverse biological pro-
cesses, including immune response, development, cell
growth, and survival [12,13]. However, continuous acti-
vation of NF-κB leads to carcinogenesis and tumor deve-
lopment [14].
Current anti-tumor treatments, such as radiotherapy,
chemotherapy, immunotherapy, and suicide gene therapy,
act on tumor by inducing tumor cell apoptosis [15,16].
Evidence have shown that activated NF-κB can induce the
expression of anti-apoptotic genes, and that the consistent
activation of NF-κB is probably involved in tumor
drug-resistance development [17,18]. As a result, we
hypothesized that NF-κB mediates the up-regulation of
anti-apoptotic gene expression, which is induced by
HBx protein that contributes to the development of the
drug-resistance of HBV-integrated HCC.
Generally, new drugs are needed to solve the problem
of drug-resistance in chemotherapy. However, this
expectation is a little unrealistic when the long drug-
development period and high failure ratio is considered.
Thus, it seems more reasonable to select an “adjuvant
drug” that can increase the sensitivity of tumor cells to
chemotherapeutic drugs. Adjuvant drug can improve the
anti-tumor effect of chemotherapeutic drugs and reduce
the drug dose and toxicity.
Interferon-α (IFN-α) has been discovered based on
its antiviral activity. IFN-α is one of the drugs first
approved by FDA for the treatment of chronic HBV
infection, and has been clinically applied for 20 years
[19]. IFN-α exerts its antiviral effect by inducing the
expression of some protective host proteins such as
PKR and MyD88. Recent studies have shown thatIFN-α can accelerate TNF-induced tumor cell apop-
tosis by up-regulating Fas expression [20], while other
studies have shown that pretreatment with IFN-α can
inhibit the TRAIL-mediated NF-κB activation, thereby
increasing the response of hepatoma cells to TRAIL-
induced apoptotic signal [21]. Based on these facts,
we examined whether IFN-α can improve chemo-
sensitivity in tumor cells by inhibiting the HBx
protein-induced activation of the NF-κB signaling pathway
and whether IFN-α can contribute to the reversion of
tumor drug-resistance. Moreover, we hypothesize that
IFN-α may be a candidate adjuvant drug for HBV-
integrated HCC chemotherapy.
Results
Introduction of HBx contributed to the drug-resistance
development of Huh7 cells
Transfection of HBx reduces the chemosensitivity of Huh7
cells
To determine the impact of HBx protein on the drug-
sensitivity of hepatoma cells, we constructed a pcDNA3.
1-HBx plasmid, an expression vector of HBx protein, and
then transfected it into Huh7 cells. After verifying the
expression of HBx in Huh7-HBx cells (data not show), we
performed MTT experiment, and then ayalyzed by
GraphPad Prism 5 software to evaluate the destructive
effect of ADM and Amn on Huh7, Huh7-3.1, and Huh7-
HBx cells, respectively. The IC50 of ADM and Amn in
Huh7-HBx cells were 2.317 and 1.828 times of those in
Huh7-3.1 cells (P<0.01), as shown in Figure 1A. We fur-
ther assessed the apoptosis ratio in Huh7, Huh7-3.1, and
Huh7-HBx cells by Annexin V/PI analysis after treatment
with 1 μg/ml ADM for 24 h. We found a significantly
lower apoptosis ratio in Huh7-HBx (15.78 ± 3.54,),
compared with Huh7 (31.09 ± 4.54,) and Huh7-3.1 cells
(30.15 ± 4.41,) (Figure 1B). In addition, the ADM-
induced G2/M growth arrest in Huh7-HBx cells were
significantly lower compared with that in Huh7 and
Huh7-3.1 cells (Figure 1C).
Transfection of HBx reduces the chemosensitivity of Huh7 in
xenograft mice model
Nude mice were inoculated s.c. into the right armpit
with Huh7, Huh7-HBx, or Huh7-3.1 cells. After three
weeks, 5-FU (25 mg/kg × d), ADM (2 mg/kg × d), or nor-
mal saline was administered by i.p. injection. Table 1
shows that the administration of 5-FU in the Huh7 and
Huh7-3.1 hepatoma models for 14 days reduced the
tumor growth by 74.20, and 71.18,, respectively, and the
administration of ADM reduced the tumor growth by
68.36, and 69.10,, respectively. Meanwhile, the i.p. ad-
ministration of 5-FU or ADM in the Huh7-HBx
Figure 1 Increase in drugs resistance induced by HBx. A) The IC50 value of ADM and Amn against Huh7, Huh7-3.1, and Huh7-HBx cells
respectively. Huh7-HBx cells represent a higher resistance of 2.317 and 1.828 times, respectively, than Huh7-3.1 cells against these two
chemotherapeutic drugs. B) After treatment with ADM for 24 h, the Annexin V/PI assay was used for the analysis of cell apoptosis. A significantly
less degree of apoptosis was found in Huh7-HBx cell than in Huh7-3.1 cell (P < 0.05). C) Cell cycle analysis of Huh7, Huh7-3.1 and Huh7-HBx cells
after 24 h of treatment with ADM, as determined by flow cytometry for DNA content.
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tion in tumor growth, with only 39.56, and 42.26, re-
spectively (P<0.01).
These data indicated the direct role of HBx protein in
regulating the drug-resistance of hepatoma cells.HBx-induced drug resistance are associated with NF-κB
pathway activation
HBx induces NF-κB pathway activation
Activated NF-κB1/p65 would translocate from the cyto-
plasm to the nucleus, hence, we evaluated NF-κB activation
Table 1 HBx reduces the chemosensitivity of Huh7 in xenograft mice model
Tumor Treatment (n = 5) Dosage (mg/kg × d) Tumor weight (g) Growth inhibition (%) P, t-Test
Huh7 Vehicle 0 2.089 ± 0.229 - -
Huh7-3.1 Vehicle 0 2.11 ± 0.259 - p>0.05
Huh7-HBx Vehicle 0 2.068 ± 0.195 - p>0.05
Huh7 5-FU 25 0.528 ± 0.19 74.72 -
Huh7-3.1 5-FU 25 0.608 ± 0.253 71.18 p>0.05
Huh7-HBx 5-FU 25 1.25 ± 0.307 39.56 p<0.01
Huh7 ADM 2 0.661 ± 0.218 68.36 -
Huh7-3.1 ADM 2 0.652 ± 0.162 69.1 p>0.05
Huh7-HBx ADM 2 1.194 ± 0.211 42.26 p<0.01
Student’s t test was used to assess the significance of tumor growth inhibition of each group compared with vehicle (normal saline -treated group).
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pared cytoplasmic and nuclear localization of p65 by con-
focal. Figure 2A shows that p65 was mainly localized in
the cytoplasm of the Huh7-3.1 cells, while a considerable
percentage of p65 was found in the nucleus of Huh7-HBx
cells. However, after incubating the Huh7-HBx cells with
an IKKβ specific inhibitor, IMD-0354, for 24 hours, the
level of p65 in the nucleus decreased to some extent.
Subsequently, we determined the phosphorylation of
IκBα, a cytoplasmic inhibitory molecule of NF-κB. Western
blot analysis revealed the presence of phosphorylated IκBα
in Huh7-HBx cells, while pretreated with IMD-0354 for
24 h decreased the level of phosphorylated IκBα in
Huh7-HBx cells significantly (Figure 2B).
HBx-induced drug resistance can be abolished by inhibiting
the NF-κB pathway
We further assessed whether the HBx-induced drug re-
sistance are affected by blocking the NF-κB pathway.
Annexin V-FITC/PI analysis showed that the apoptosis
ratio of Huh7-HBx cells after incubated with IMD-0354
(2 μM) increased to some extent (Figure 3A).
Recent studies indicated that the transactivating forms
of NF-κB (e.g., dimers containing the p65/RelA subunit)
may up-regulate the expression of the MDR1/P-gp gene,
which is involved in drug resistance. We also assessed
whether HBx-induced drug resistance are associated
with the up-regulation of MDR-associated genes, such
as MDR1, MRP1, LRP1, and ABCG2. As shown in
Figure 3B, the expression of these genes dramatically
increased in Huh7-HBx, but maintained at a stable level
in Huh7-3.1 cells. Huh7 cells were set as calibrator for
comparison with others. However, the expression of
MDR-associated genes dramatically decreased after
incubating the Huh7-HBx cells with 2 μM IMD-0354 for
24 h (Figure 3B).
Cancer cells would activate the NF-κB pathway to
up-regulate the expression of anti-apoptotic genes, such
as c-IAP-1, c-IAP-2, Bcl-Xl, Gadd45β, and Survivin, toavoid apoptosis. We further assessed whether the HBx-
induced drug resistance are associated with the up-
regulation of the expression of these anti-apoptotic
genes. We found a significant up-regulation of Gadd45β,
Survivin, and c-IAP-1 level in Huh7-HBx cells, com-
pared with that in Huh7-3.1 cells. However, the ex-
pression of these genes dramatically decreased after
incubating the Huh7-HBx cells with 2 μM IMD-0354 for
24 h (Figure 3C).
These results suggested that HBx-induced drug resist-
ance are mediated by the NF-κB pathway, and this drug
resistance can partly be abolished by inhibiting NF-κB
activation through IMD-0354 treatment.Interferon-α sensitizes HBx-expressing hepatoma cells to
ADM by inhibiting the HBx-mediated NF-κB activation
Confocal and Western blot analysis showed that IFN-α
decreased the NF-κB activity in HBx-producing cells
(Figure 2A, 2B). Based on this result, the inhibition of
NF-κB activity by IFN-α was expected to decrease the
resistance to ADM. Therefore, we analyzed the viability
and apoptosis in Huh7-HBx cells, which have high NF-κB
activity, by treating these cells with ADM and IFN-α.
Compared with Huh7-HBx cells treated with either IFN-α
or ADM, the cells treated with both IFN-α and ADM
clearly showed an increase in annexin V binding of the
cell population (Figure 4A).
The tumor growth assay in nude mice also showed that
IFN-α can sensitize HBx-expressing hepatoma cells to
ADM treatment. The weight of the neoplasms from ADM
+ IFN-α treated mice were significantly smaller than the
tumors of the Huh7-HBx implanted mice (P < 0.05). In
addition, daily administration with 5 mg/kg of IMD-0354
(NF-κB inhibitor) combined with ADM also significantly
suppressed tumor expansion in Huh7-HBx bearing nude
mice compared with ADM only (Table 2).
The real time-PCR results for Gadd45β, Survivin, and
c-IAP-1 showed that the expression of these anti-apoptotic
Figure 2 HBx induces NF-κB pathway activation. A) Confocal immunofluorescence analysis of Huh7-3.1, Huh7-HBx, and Huh7-HBx treated
with IMD-0354 or IFN-α, using p65 antibody (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red). P65 is mainly
localized in the cytoplasm of Huh7-3.1 cells, while was partly translocated into the nucleus of Huh7-HBx cells. However, the level of p65 in the
nucleus of Huh7-HBx cells decreased to some extent after treatment with IMD-0354 or IFN-α. B) The expression level of phosphorylated IκBα was
detected by Western blotting (lane 1, Huh7 cells; lane 2, Huh7-3.1 cells; lane 3, Huh7-HBx; lane 4, Huh7-HBx treated with IMD-0354; lane 5, Huh7-HBx
treated with IFN-α).
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in Huh7-HBx cells (Figure 4B).
These results suggested that IFN-α-mediated drug
resistance disruption may be associated with the down-
regulation of anti-apoptotic gene expression by inhibiting
NF-κB activation.
Discussion
Chronic infection of hepatitis B and C can advances
to cirrhosis and HCC. Recent studies have reported
that HepG2.2.15 cells (HBV-producing cells) exhibit
higher resistance to 5-FU than HepG2 cells, indi-cating a close relationship between HBV infection
and HCC drug resistance [6]. However, the under-
lying mechanism remains unclear. HBx gene, the
smallest open reading frame in viral DNA, encodes a
154-amino acid length protein. HBx functions in a
variety of signaling pathways including the NF-κB-re-
lated pathways; hence, may have an important role in
HBV-related tumorigenesis and tumor progression
[22,23]. The present study aims to investigate the role
of HBx in HBV-induced drug resistance of HCC, and
examine whether such drug-resistance can be re-
versed by IFN-α treatment.
Figure 3 HBx up-regulated the expression of MDR-associated genes and anti-apoptosis genes mediated by the NF-κB pathway.
A) Apoptosis index of Huh7, Huh7-3.1, and Huh7-HBx cells after treatment with ADM. The apoptosis ratio in Huh7-HBx cells was significantly
lower than that of the Huh7-3.1 cells (P < 0.01). However the level of apoptosis index in the Huh7-HBx cells increased to some extent after co-
treatment with the NF-κB pathway inhibitor, IMD-0354 (P<0.05). B) The expression of MDR associated genes of Huh7, Huh7-3.1 and Huh7-HBx
cells was detected by real-time RT-PCR, with β-actin as internal control. The gene expression levels of Huh7 cells were set as calibrator to
compare with others. C) The transcript level of anti-apoptosis genes in Huh7, Huh7-3.1, and Huh7-HBx cells was detected by real-time RT-PCR analysis
with β-actin as internal control. Logarithmic scale expression values were normalized to Huh7 (ref =1, n = 3).
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Figure 4 Interferon-α diminishes Huh7-HBx cells resistance to ADM. A) Apoptotic index quantitated by FACS. Compared with Huh7-HBx
cells treated with either IFN-α or ADM, the cells treated with both IFN-α and ADM clearly showed an increase in annexin+/PI- & annexin+PI+ cell
population. Data are showed as mean ± SD, and statistically analyzed with Student’s t test assay. * P < 0.05, ** P < 0.01, each cells v.s. controle
(non-treated Huh7-HBx cells). B) The transcript level of the anti-apoptosis genes in Huh7-HBx cells (control) and IFN-α or IMD-0354 pretreated
Huh7-HBx cells were detected by real-time RT-PCR analysis, with β-actin as internal control. Logarithmic scale expression values were normalized
to Huh7-HBx (ref =1, n = 3).
Table 2 IFN-α improve the chemosensitivity of Huh7-HBx








Vehicle 2.102 ± 0.165 - -, -
ADM 1.31 ± 0.159 37.69 p<0.01, -
IFN-α 1.75 ± 0.135 16.73 p<0.05, -
ADM + IFN-α 0.725 ± 0.098 65.49 p<0.01, *p<0.01
ADM + IMD 0.622 ± 0.095 70.41 p<0.01, *p<0.01
Student’s t test was used to assess the significance of tumor growth inhibition
between each group. Left “p”: each group compared with vehicle (saline
treated Huh7-HBx bearing group). Right “*p”: ADM + IFN-α or ADM + IMD
treated group compared with ADM treated group.
Liu et al. Virology Journal 2013, 10:168 Page 7 of 11
http://www.virologyj.com/content/10/1/168We first used in vitro HBx-expression hepatoma cell
lines to analyze the effect of HBx gene induction, and
found that Huh7-HBx cells have increased drug resist-
ance than Huh7-3.1 cells. Our data showed that the IC50
values of Huh7-HBx cells against ADM and Amn were
2.317 and 1.828 -folds higher than those of Huh7-3.1
cells, respectively. When treated with 1 μg/ml ADM,
Huh7-HBx cells exhibited significantly lower apoptosis
rate and G2/M growth arrest than Huh7-3.1 cells. We
also used HepG2 and SMMC-7721(SMMC) hepatoma
cell lines, along with Huh-7 cells, to investigate the role
of HBx in the HBV-induced drug resistance of HCC.
After transfection with pcDNA3.1-HBx, HepG2-HBx
and SMMC-HBx also exhibited increased drug resist-
ance than the pcDNA3.1 vector transfected cells (data
not shown). We further used a HCC murine model to
confirm the HBx-induced drug resistance. The adminis-
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the Huh7-3.1 group by approximately 70, while the
Huh7-HBx group exhibited much less reduction in
tumor growth, with only about 40, (P<0.01). All these
results show that HBx is closely related to the HBV-
induced drug resistance of HCC.
NF-κB is not a single protein, but a collection of dimeric
transcription factors composed of members of the Rel
family with five closely related DNA binding proteins:
RelA (p65), RelB, c-Rel, NF-κB1/p50, and NF-κB2/p52. In
resting cells, NF-κB dimers are sequestered in the cy-
toplasm as latent complexes through binding to the
members of a family of ankyrin repeat domain (ARD)-
containing inhibitors called IκB (inhibitor of κB) proteins,
which interact with the RHD of NF-κB proteins [24].
There are two distinct NF-κB activation pathways: canon-
ical (or traditional) and non-canonical (or alternative)
pathways. Our results have demonstrated that the HBx-
induced drug resistance of HCC is associated with the
activation of NF-κB canonical pathways, which was based
on inducible IκBα degradation, allowing NF-κB dimers
(mainly p65/p50 dimers) to accumulate in the nucleus
and activate transcription. The presence of spontaneously
phosphorylated IκBα and activated NF-κB in the Huh7-
HBx cells was observed through immunofluorescence and
Western blotting analysis. Further blocking test with se-
lective IKKβ inhibitor, IMD-0354 (blocks IκBα phosphor-
ylation and prevents the induction of p65 nuclear
translocation), which against NF-κB canonical pathway in-
dicated a partial reversion of drug resistance of Huh7-HBx.
After treatment with IMD-0354 for 24 h, Huh7-HBx
exhibited increased apoptosis in response to ADM and
5-FU. Moreover, the HBx-induced up-regulation of drug
resistance-associated genes (such as MDR1, MRP1, LRP1,
and ABCG2) and anti-apoptotic genes, such as Gadd45β,
Survivin, and c-IAP-1, was repressed. Moreover, our data
indicated that HBx may induce HCC drug resistance by ac-
tivating the NF-κB canonical pathways. Hung et al. also
demonstrated that HBV pre-S2Δ (HBV pre-S2 mutant
large surface) protein can induce resistance to 5-FU treat-
ment in Huh-7 cells through the induction of NF-κB p65
[25]. However, another study showed that HBV causes
drug resistance through the non-canonical (alternative)
pathway, in which NIK phosphorylates ΙΚΚα, thereby acti-
vating NF-κB [6]. Thus, we hypothesized that other HBV
proteins may contribute to progression of HCC drug
resistance by activating the NF-κB alternative pathways in
an IKKβ-independent way.
Several drugs, including ADM and docetaxel, have been
developed for treating breast, prostate, and lung cancers
with great success. However, their anticancer effects are
diminished because of their intrinsic or acquired drug
resistance, which involves the over-expression of
P-glycoprotein (P-gp) or multidrug resistance protein 7(MRP7) [26]. Several strategies have been studied to over-
come MDR mechanism including the use of novel drug
delivery systems, co-administration of P-gp inhibitors, and
the development of novel anticancer drugs that can cir-
cumvent MDR. Scientists have also successfully discovered
several new compounds to overcome MDR. Ixabepilone,
for example, has been approved by the FDA as a drug for
MDR breast cancer [27]. However, an effective drug
against MDR HCC has not been found yet. Thus, selecting
“adjuvant drug” that can increase the sensitivity of hepa-
toma cells to existing drugs will contribute significantly to
the progress of cancer chemotherapy.
IFN-α has an essential role in antiviral host defenses
and has been used clinically for the treatment of chronic
HBV infection [28]. IFN-α cannot kill the viruses dir-
ectly; however, it functions by activating the transcrip-
tion factor of antiviral proteins and inducing the
synthesis of these proteins. These antiviral proteins, such
as PKR (double strand RNA activated protein kinase),
inhibit virus replication by inhibiting protein synthesis
by phosphorylate the translation initiation factor eIF-2
[29]. Moreover, PKR can also interact with IKKβ and
interfere with the NF-κB signaling pathways [30].
We found that IFN-α treatment improved the drug sen-
sitivity of HBx-expressing hepatoma cells. The Huh7-HBx
cells in the IFN-α treated group exhibited a remarkably
higher apoptosis in response to 5-FU and ADM than the
untreated group. The tumor growth assay in nude mice
also showed that IFN-α can sensitize Huh7-HBx cells to
ADM treatment. The weight of the neoplasms from ADM
+ IFN-α treated mice were significant lower than the
tumors from ADM treated Huh7-HBx-bearing mice
(P < 0.05). In addition, daily administration with 5 mg/kg
of IMD-0354 (NF-κB inhibitor) combined with ADM also
significantly suppressed tumor expansion in Huh7-HBx-
bearing nude mice compared with ADM only. Moreover,
the up-regulation of anti-apoptotic gene expression was
largely inhibited by IFN-α treatment. Our study showed
that IFN-α treatment significantly reduced the nuclear
concentration of p65 and the level of phosphorylated IκBα
in Huh7-HBx cells, which was consistent with the effect
of IMD-0354 pretreatment. These results indicated that
IFN-α may inhibit one essential step in NF-κB canonical
pathway, and thus reduced the HBx-induced NF-κB acti-
vation. However, the specific step of IFN-α interfering
with the NF-κB canonical pathway is still unknown. Thus,
further investigation is needed to verify whether IFN-α
acts directly on IKKβ as IMD-0354 or suppress the deg-
radation of IκBα, IκBβ, and p105.
In conclusion, we indicated that HBx induced drug
resistance was associated with NF-κB canonical pathway
activation. We also demonstrated that IFN-α can inhibit
the HBx-mediated activation of NF-κB. These results
suggest that IFN-α treatment may be a useful strategy
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Huh7 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (Gibco) supplemented with 10, fetal bovine
serum (FBS, Gibco). The stable transfected Huh7-HBx
and Huh7-3.1 cells were cultured in DMEM supple-
mented with 10, FBS and 800 μg/ml G418.
The construction of pcDNA3.1-HBx plasmids and stable
transfection
The expression vector pcDNA3.1-HBx was constructed by
inserting HBx DNA fragments into pcDNA3.1 vector. The
primers were: HBx-up: 5′-acttaagcttgccaccatggctgctaggc
tg-3′, HBx-down:5′- tagactcgagttacagatcctcttctgagatgagtttt
tgttcggcagaggtgaaaaagttg-3′. After by PCR amplification
using DNA sample of HepG2.2.15 cells, which is an HBV
cell model by transducing of HBVayw genotype into
HepG2 cells, the HBx DNA fragment was inserted between
the Hind III and Xho cloning sites of the pcDNA3.1 vector.
And after amplification in DH-5α, we used the plasmid
DNA mini kit (Simgen) to purify the plasmids. Huh7 cells
at 70-80, confluence were transfected with plasmids, using
lipofectamine 2000 (Life Technologies, Inc.). Plasmid trans-
fections were performed according to protocols supplied
with the reagents. At 48 h post-transfection, cells were cul-
tured in the presence of 1.5 mg/ml G418. After 21 ~ 2cbu
in selective medium, individual G418-resistant colonies
were isolated. Expression of HBx in Huh7-HBx cell lines
was verified by RT-PCR and Western Blot. The control cell
line (Huh7-3.1) was generated from cells transfected with
the vector alone and selected using G418. After isolation of
resistant clones, the concentration of G418 was changed to
800 μg/mL.
MTT assay
MTT is a colorimetric technique for detecting the re-
duction of MTT (Methyl thiazolyl tetrazolium, Sigma)
by mitochondrial dehydrogenase to blue formazan prod-
uct, which reflects the normal function of mitochondria
and hence the measurement of cytotoxicity cell and via-
bility. The cells were seeded onto 96-well plates and
treated with ADM (doxorubicin) or Amn (amonafide)
(Sigma) for 72 h. The medium was removed, and the
cells were incubated with a solution containing 0.5 mg
MTT/mL phosphate-buffered saline at 37°C for 4 h. The
MTT solution was removed and the cells were overlaid
with 100 μL/well DMSO for 15 min at 37°C. The OD
value was measured using a Bio-Rad microplate reader
at 570 nm with DMSO as blank. Triplicate wells were
assayed for each condition. Percent growth inhibition ofcells exposed to treatments was calculated as follows:,
Inhibition = 100 − (Test OD/Non-treated OD) × 100. The
data were then analysesed by GraphPad Prism 5 software
to get IC50 value.
Cell apoptosis and cell cycle analysis by FACS
Cell apoptosis analysis: Huh7, Huh7-HBx and Huh7-3
.1cells were plated and grown overnight until they reach
80, confluence, then the cells were treated with 1 μg/ml
ADM or/and IMD-0354. Subsequently, detached cells in
the medium were collected, and the remaining adherent
cells were released by trypsinization. The cells were
washed with phosphate-buffered saline (PBS) and
resuspended in 250 μL binding buffer (annexinV-FITC
kit; BECKMAN COULTER) containing 5 μL of annexin
V-FITC stock and 10 μL of 20 μg/mL propidium iodide
(PI). After incubated for 10 min at room temperature in
a light protected area, the samples were analyzed by
FACS (BECKMAN COULTER FC500 MPL) using
muticycle software. We could discriminate intact cells
(annexin-/PI-) from apoptotic cells (annexin+/PI- &
annexin+PI+) and necrotic cells (annexin-/PI+) after
treatment with ADM.
Cell cycle analysis: Cell cycle analysis was performed
by propidium iodide staining (Sigma, St. Louis, MO).
Cells were fixed in 70, ethanol, incubated with 0.1,
RNase A in PBS at 37 C for 30 min and resuspended in
PBS containing 25 μg/mL propidium iodide (PI) for
30 min at room temperature. The stained cells were ana-
lyzed for DNA content by FACS (BECKMAN COULTER
FC500 MPL) using muticycle software.
Tumor growth assays in nude mice
In vivo seven-week-old specific pathogen-free male Nude
mice (weight, 18 ~ 22 g) were supplied by Zhejiang Aca-
demy of Medical Science. And the study was approved by
the animal ethics committee of Zhejiang University (ap-
proval ID, Zju2009-1-01-025Y). Mice were inoculated s.c.
into the right armpit with Huh7, Huh7-HBx or Huh7-3
.1cells. After 3 weeks, 5-fluorouracil (25 mg/kg), ADM
(2 mg/kg) or/and IFN-α (4 MIU/kg × d), IMD-0354
(5 mg/kg) was administered by i.p. injection once a day
for 14 days. Saline was injected in nude mice as a control.
The inhibition rate was calculated as [(average tumor
weight of normal saline group - average tumor weight
of test group)/average tumor weight of normal saline
group] × 100.
Immunofluorescence and confocal analysis
Cells were attached to the gelatin-coated glass coverslip
overnight. Then the coverslips were washed with PBS
three times and then fixed with 4, paraformaldehyde for
10 min at 4°C. After treated with 0.3, Triton X-100 for
10 min, then washed with PBS again, and incubated with
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non-specific adsorption of the antibodies to the coverslip.
Then incubated with primary antibodies against NF-κB
p65 (1:100, cell signaling) at 4°C overnight. The coverslips
were then washed in PBS and incubated with FITC-
coupled secondary antibodies (1:200, Santa Cruz) for
30 min at room temperature. And then incubated with
Alexa Fluor 555 phalloidin for 20 min at room tem-
perature. After washed in PBS,the cell coverslips were
mount with glycerol and examined by confocal (Olympus).
Western blot analysis
To determine the levels of protein expression, whole-cell
extracts were prepared and fractionated using SDS-PAGE.
After electrophoresis, the proteins were electrotransferred
onto nitrocellulose membranes, blotted with phosphory-
lated IκBα antibody, and detected using an enhanced
chemiluminescence regent (Amersham). Blots were visu-
alized by ECL-associated fluorography (Pierce Inc.).
Semi-quantitative- real time PCR (SQ-real time-PCR)
The cells were collected by trypsinization, and then the
total RNA was extracted using TRIzol Reagent (Invitrogen,
USA) according to the manufacturer’s protocol. The
cDNA was produced by RT using Reverse transcription kit
(Takara). Then the products were used for analysis on an
ABI PRISM 7900 Sequence Detection System using SYBR®
Premix Ex TaqTM kit (Takara). The expression of the fol-
lowing genes was evaluated: MRP-1, LRP, MDR-1, ABCG2,
Gadd45β, Survivin and c-IAP-1. β-actin was used as the
endogenous control to normalize all the above target
genes; to determine the relative quantification, the com-
parative threshold cycle (Ct) method was used. The gene
expression levels of Huh7 cells or Huh7-HBx cells were
set as calibrator to compare with others. All Assays-on-
Demand™ Gene Expression Products consisted of target
assays and endogenous control assays to amplify and
detect expression of specific RNA sequences.
Statistical analyses
Data are expressed as mean ± SEM; all values were cal-
culated, graphed and analyzed statistically using Student’s
t-test. P < 0.05 was considered statistically significant.
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